Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMC-VAC: Perennial Malaria Chemoprevention in the Malaria Vaccine Era
NCT07322068Phase 4Not yet recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- Jun 2033
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of sulfadoxine + pyrimethamine + amodiaquine, dihydroartemisinin + piperaquine in Malaria, sponsored by Stanford University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sulfadoxine + pyrimethamine + amodiaquinedihydroartemisinin + piperaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT07322068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322068.